CSPC Pharmaceutical Group (HKG:1093) has obtained approval from China's National Medical Products Administration to conduct clinical trials of its Valsartan Levoamlodipine Maleate tablets in China, a Friday bourse filing said.

The drug is indicated for the treatment of primary mild and moderate hypertension that cannot be effectively controlled by monotherapy.

Shares of the pharmaceutical firm closed over 6% higher on Friday.

Price (HKD): $4.99, Change: $+0.30, Percent Change: +6.40%